| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 854.5MM | +15% |
| Gross Profit | 430.3MM | +12% |
| Cost Of Revenue | 424.2MM | +18% |
| Operating Income | 103.5MM | -17% |
| Operating Expenses | 326.8MM | +27% |
| Net Income | 205.5MM | - |
| R&D | 83.5MM | +17% |
| G&A | 211.2MM | +19% |
| Professional Service | - | - |
| Amortization | 13.7MM | +19% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
BILLERICA, Mass., April 22, 2024--Bruker Corporation (Nasdaq: BRKR) today announced that it has entered into a definitive acquisition agreement with NanoString Technologies, Inc., headquartered in Seattle, Washington, a leading provider of solutions for spatial transcriptomics and gene expression analysis.
Bruker made an offer roughly two months after Nanostring filed for bankruptcy protection and said it may restructure.
Bruker's (BRKR) latest novel technology facilitates the widespread application of NMR in academic basic and clinical research.
ASILOMAR, Calif., April 08, 2024--Bruker Corporation (Nasdaq: BRKR), the leading provider of nuclear magnetic resonance (NMR) spectroscopy solutions, announces the introduction of novel high-resolution solid-state NMR scientific capabilities that can enable unprecedented structural biology discoveries in large proteins, membrane proteins and in protein aggregates.
ASILOMAR, Calif., April 08, 2024--Bruker Corporation (Nasdaq: BRKR), the leading provider of nuclear magnetic resonance (NMR) systems, today announces novel magnet technology and analytical solutions to support broad adoption of NMR in academic basic and clinical research, as well as in biopharma drug discovery, development and process analytical technologies (PAT).
Strategic partnership expands Biognosys’ services to include Alamar’s NULISA assays as well as joint scientific research in biofluid-based proteomicsComplementary value of Biognosys’ DIA-MS unbiased proteomics platform and Alamar’s game-changing immunoassay platforms to be presented at the AACR 2024 Annual Meeting ZURICH, Switzerland and FREMONT, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Biognosys, a global leader in mass spectrometry-based proteomics, and Alamar Biosciences, Inc., a company po
BILLERICA, Mass., April 01, 2024--Bruker Corporation (NASDAQ: BRKR) has been selected as the Instrument Business Outlook (IBO) ‘Company of the Year’ for 2023. IBO cited Bruker’s double-digit organic revenue growth in 2023 in all major regions, and in all business groups, demonstrating a transformed portfolio and operational strength.
Bruker Corporation (BRKR) outperforms the industry due to its strengthening portfolio and robust quarterly results.
Bruker (BRKR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Investors are upbeat about Bruker (BRKR) led by strong NANO group prospects and strong guidance.